A citation-based method for searching scientific literature

Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Nobumichi Saito, Tomohiko Kanaoka, Hiroyuki Sakai, Takayuki Furuki, Tomoya Umezono, Shun Ito, Daisuke Suzuki, Hiroshi Takeda, Fuyuki Minagawa, Hisakazu Degawa, Hareaki Yamamoto, Hideo Machimura, Keiichi Chin, Toshimasa Hishiki, Masahiro Takihata, Kouta Aoyama, Shinichi Umezawa, Kohsuke Minamisawa, Togo Aoyama, Yoshiro Hamada, Yoshiro Suzuki, Masahiro Hayashi, Yutaka Hatori, Kazuyoshi Sato, Masaaki Miyakawa, Kouichi Tamura, Akira Kanamori. Diabetes Technol Ther 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.
Colin Baigent, William G Herrington, Josef Coresh, Martin J Landray, Adeera Levin, Vlado Perkovic, Marc A Pfeffer, Peter Rossing, Michael Walsh, Christoph Wanner,[...]. Kidney Int 2017
57
100

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
227
100

Predictors and the Subsequent Risk of End-Stage Renal Disease - Usefulness of 30% Decline in Estimated GFR over 2 Years.
Wen Xiu Chang, Shinichiro Asakawa, Daigo Toyoki, Yoshikazu Nemoto, Chikayuki Morimoto, Yoshifuru Tamura, Tatsuru Ota, Shigeru Shibata, Yoshihide Fujigaki, Zhong Yang Shen,[...]. PLoS One 2015
27
100

Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population--the Ohasama study.
Masaaki Nakayama, Hirohito Metoki, Hiroyuki Terawaki, Takayoshi Ohkubo, Masahiro Kikuya, Toshinobu Sato, Keisuke Nakayama, Kei Asayama, Ryusuke Inoue, Junichiro Hashimoto,[...]. Nephrol Dial Transplant 2007
149
100

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
100

Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM 40).
Hiroki Yokoyama, Mariko Oishi, Hiroshi Takamura, Katsuya Yamasaki, Shin-Ichiro Shirabe, Daigaku Uchida, Hidekatsu Sugimoto, Yoshio Kurihara, Shin-Ichi Araki, Hiroshi Maegawa. BMJ Open Diabetes Res Care 2016
41
100

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
G L Bakris, M Williams, L Dworkin, W J Elliott, M Epstein, R Toto, K Tuttle, J Douglas, W Hsueh, J Sowers. Am J Kidney Dis 2000
999
100

Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai, Tomoya Umezono, Shun Ito, Daisuke Suzuki, Hiroshi Takeda, Fuyuki Minagawa,[...]. J Diabetes Investig 2021
1
100

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki, Masayuki Kato, Sumie Okahata, Hisayuki Katsuyama, Mikiko Haraguchi, Ai Morita, Ken Ohashi, Kazuo Hara,[...]. Lancet Diabetes Endocrinol 2017
110
100

A population-based study of the incidence and outcomes of diagnosed chronic kidney disease.
Nicholas Drey, Paul Roderick, Mark Mullee, Mary Rogerson. Am J Kidney Dis 2003
248
100

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.
William L Baker, Lindsay R Smyth, Daniel M Riche, Emily M Bourret, Kevin W Chamberlin, William B White. J Am Soc Hypertens 2014
258
100


The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).
Satoshi Umemura, Hisatomi Arima, Shuji Arima, Kei Asayama, Yasuaki Dohi, Yoshitaka Hirooka, Takeshi Horio, Satoshi Hoshide, Shunya Ikeda, Toshihiko Ishimitsu,[...]. Hypertens Res 2019
305
100

Revised equations for estimated GFR from serum creatinine in Japan.
Seiichi Matsuo, Enyu Imai, Masaru Horio, Yoshinari Yasuda, Kimio Tomita, Kosaku Nitta, Kunihiro Yamagata, Yasuhiko Tomino, Hitoshi Yokoyama, Akira Hishida. Am J Kidney Dis 2009
100

Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
Kazuo Kobayashi, Masao Toyoda, Noriko Kaneyama, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai, Masahiro Takihata, Tomoya Umezono, Shun Ito, Daisuke Suzuki,[...]. J Diabetes Res 2019
2
100

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
William L Baker, Leo F Buckley, Michael S Kelly, John D Bucheit, Eric D Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L Dixon. J Am Heart Assoc 2017
77
100

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
100

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
100


GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
Andrew S Levey, Lesley A Inker, Kunihiro Matsushita, Tom Greene, Kerry Willis, Edmund Lewis, Dick de Zeeuw, Alfred K Cheung, Josef Coresh. Am J Kidney Dis 2014
261
100

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
100





Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.
Hiddo J Lambers Heerspink, Tobias F Kröpelin, Jarno Hoekman, Dick de Zeeuw. J Am Soc Nephrol 2015
147
100



Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
Tazeen H Jafar, Paul C Stark, Christopher H Schmid, Marcia Landa, Giuseppe Maschio, Paul E de Jong, Dick de Zeeuw, Shahnaz Shahinfar, Robert Toto, Andrew S Levey. Ann Intern Med 2003
740
100

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
H J L Heerspink, E Johnsson, I Gause-Nilsson, V A Cain, C D Sjöström. Diabetes Obes Metab 2016
117
100

Comparative mortality from cardiovascular disease in patients with chronic renal failure.
J H Brown, L P Hunt, N P Vites, C D Short, R Gokal, N P Mallick. Nephrol Dial Transplant 1994
122
100

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
224
100

The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease.
Takayuki Furuki, Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Hiroyuki Sakai, Kazuyoshi Sato, Masaaki Miyakawa, Kouichi Tamura, Akira Kanamori. J Clin Hypertens (Greenwich) 2020
1
100

Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kazuo Kobayashi, Masao Toyoda, Moritsugu Kimura, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai, Masahiro Takihata, Tomoya Umezono, Shun Ito, Daisuke Suzuki,[...]. Diab Vasc Dis Res 2019
7
100

Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring.
Kazuo Kobayashi, Masao Toyoda, Moritsugu Kimura, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai, Masahiro Takihata, Tomoya Umezono, Shun Ito, Daisuke Suzuki,[...]. Clin Exp Hypertens 2019
3
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.